Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination with Monoclonal Antibody to OX40 (MEDI6469) in Patients with Metastatic Colorectal Cancer
This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.
* Patients who will undergo staged liver resections are included in this study. In these cases, preoperative MEDI6469 will be given prior to the initial procedure.
*Patients with small <3 cm tumors located >2 cm away from central bile ducts will be considered for either radiofrequency ablation or resection, the choice of which will be determined at the time of surgery.
* Metastatic disease outside of the liver that is not considered surgically resectable or curable.
Philippa Newell, M.D.
Earle A Chiles Research Institute (EACRI)
- Oncology and Hematology Care Eastside